[
  {
   "Sponsor":"Ultragenyx",
   "Sponsor-2":"",
   "Year":"2018",
   "Month":"August",
   "Date":"15",
   "name":"Metabolic",
   "id":"X-linked hypophosphatemia(HPP)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"CRYSVITA",
   "Active Ingredient":"burosamab-twza",
   "Treatment Type":"Immunotherapy",
   "MOA":"FGF23-blocking monoclonal antibody",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"NA",
   "Purchase Month":"NA",
   "Purchase Date":"NA",
   "Purchase Year":"NA",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"NA",
   "Acq date":"NA",
   "Acq year":"NA",
   "":""
  },
  {
   "Sponsor":"X4 Pharmaceuticals",
   "Sponsor-2":"",
   "Year":"2024",
   "Month":"May",
   "Date":"16",
   "name":"Immunology",
   "id":"WHIM Syndrome",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"Xolremdi",
   "Active Ingredient":"mavorixafor",
   "Treatment Type":"Gene therapy",
   "MOA":"CXC chemokine receptor 4 antagonist",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"105",
   "Purchase Month":"May",
   "Purchase Date":"9",
   "Purchase Year":"2024",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"NA",
   "Acq date":"NA",
   "Acq year":"NA",
   "":""
  },
  {
   "Sponsor":"bluebird Bio",
   "Sponsor-2":"",
   "Year":"2022",
   "Month":"August",
   "Date":"29",
   "name":"Hematology",
   "id":"ÃŸ-thalassemia",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"Zynteglo",
   "Active Ingredient":"betibeglogene autotemcel",
   "Treatment Type":"Gene therapy",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Bristol Myers Squibb",
   "Sale  Price (USD, Millions)":"95",
   "Purchase Month":"January",
   "Purchase Date":"5",
   "Purchase Year":"2023",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"NA",
   "Acq date":"NA",
   "Acq year":"NA",
   "":""
  },
  {
   "Sponsor":"Novartis",
   "Sponsor-2":"AveXis",
   "Year":"2019",
   "Month":"June",
   "Date":"24",
   "name":"Neurology",
   "id":"Spinal muscular atrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"ZOLGENSMA",
   "Active Ingredient":"onasemnogene abeparvovec-xioi",
   "Treatment Type":"Gene therapy",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"NA",
   "Purchase Month":"NA",
   "Purchase Date":"NA",
   "Purchase Year":"NA",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"NA",
   "Acq date":"NA",
   "Acq year":"NA",
   "":""
  },
  {
   "Sponsor":"Biogen",
   "Sponsor-2":"",
   "Year":"2017",
   "Month":"March",
   "Date":"6",
   "name":"Neurology",
   "id":"Spinal muscular atrophy",
   "Approved Drug":"",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"SPINRAZA",
   "Active Ingredient":"Gene therapy",
   "Treatment Type":"Gene therapy",
   "MOA":"Antisense oligonucleotides",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"NA",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Genentech",
   "Sponsor-2":"",
   "Year":"2020",
   "Month":"August",
   "Date":"25",
   "name":"Neurology",
   "id":"Spinal muscular atrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"EVRYSDI",
   "Active Ingredient":"risdiplam",
   "Treatment Type":"Gene therapy",
   "MOA":"RNA splicing modifier",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"NA",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"NA",
   "Acq date":"Na",
   "Acq year":"NA",
   "":""
  },
  {
   "Sponsor":"Vertex",
   "Sponsor-2":"",
   "Year":"2024",
   "Month":"January",
   "Date":"9",
   "name":"Hematology",
   "id":"Sickle Cell Disease (SCD)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"CASGEVY",
   "Active Ingredient":"exagamglogene autotemcel",
   "Treatment Type":"Gene therapy",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"NA",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"NA",
   "Acq date":"NA",
   "Acq year":"NA",
   "":""
  },
  {
   "Sponsor":"Acadia Pharmaceuticals",
   "Sponsor-2":"",
   "Year":"2023",
   "Month":"March",
   "Date":"10",
   "name":"Neurology",
   "id":"Rett Syndrome",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"DAYBUE",
   "Active Ingredient":"trofinetide",
   "Treatment Type":"Analogs & derivatives",
   "MOA":"Glycine-proline-glutamate analog",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"NA",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"NA",
   "Acq date":"NA",
   "Acq year":"NA",
   "":""
  },
  {
   "Sponsor":"Albireo AB",
   "Sponsor-2":"",
   "Year":"2022",
   "Month":"October",
   "Date":"7",
   "name":"Hepatology",
   "id":"progressive familial intrahepatic cholestasis",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"BYLVAY",
   "Active Ingredient":"odevixibat",
   "Treatment Type":"Enzyme inhibitor",
   "MOA":"Ileal bile acid transporter (IBAT) inhibitor",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"105",
   "Purchase Month":"March",
   "Purchase Date":"16",
   "Purchase Year":"2017",
   "Acquisition":"Y",
   "Acquirer":"Ipsen",
   "Acquisition Price ":"952",
   "Acq month":"January",
   "Acq date":"9",
   "Acq year":"2023",
   "":""
  },
  {
   "Sponsor":"Alnylym Pharmaceuticals",
   "Sponsor-2":"",
   "Year":"2021",
   "Month":"February",
   "Date":"16",
   "name":"Nephrology",
   "id":"Primary hyperoxaluria type 1",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"OXLUMO",
   "Active Ingredient":"lumasiran",
   "Treatment Type":"RNA interference",
   "MOA":"Silences the HAO1 gene",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"NA",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"NA",
   "Acq date":"NA",
   "Acq year":"NA",
   "":""
  },
  {
   "Sponsor":"Rhythm Pharmaceuticals",
   "Sponsor-2":"",
   "Year":"2020",
   "Month":"December",
   "Date":"17",
   "name":"Endocrinology",
   "id":"POMC, PCSK1, and LEPR deficiency",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"IMCIVREE",
   "Active Ingredient":"setmelanotide",
   "Treatment Type":"Analogs & derivatives",
   "MOA":"Melanocortin-4 receptor agonist",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Alexion",
   "Sale  Price (USD, Millions)":"100",
   "Purchase Month":"January",
   "Purchase Date":"11",
   "Purchase Year":"2021",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Chiesi Farmaceutici S.p.A.",
   "Sponsor-2":"",
   "Year":"2023",
   "Month":"March",
   "Date":"16",
   "name":"Metabolic",
   "id":"non-central nervous system manifestations of alpha-mannosidosis",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"LAMZEDE",
   "Active Ingredient":"velmanase alfa-tycv",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":" NA ",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"N",
   "Acquirer":"NA",
   "Acquisition Price ":"NA",
   "Acq month":"NA",
   "Acq date":"Na",
   "Acq year":"NA",
   "":""
  },
  {
   "Sponsor":"AstraZeneca",
   "Sponsor-2":"Merck",
   "Year":"2020",
   "Month":"September",
   "Date":"16",
   "name":"Oncology",
   "id":"neurofibromatosis type 1  (NF1-PN)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"KOSELUGO",
   "Active Ingredient":"selumetinib",
   "Treatment Type":"Enzyme inhibitor",
   "MOA":"MEK 1/2 inhibitor",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":" NA ",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"Y",
   "Acquirer":"NA",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"United Therapeutics",
   "Sponsor-2":"",
   "Year":"2015",
   "Month":"April",
   "Date":"7",
   "name":"Oncology",
   "id":"neuroblastoma",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"UNITUXIN",
   "Active Ingredient":"dinutuximab",
   "Treatment Type":"Immunotherapy",
   "MOA":"GD2-binding monoclonal antibody",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"AbbVie",
   "Sale  Price (USD, Millions)":"350",
   "Purchase Month":"November",
   "Purchase Date":"6",
   "Purchase Year":"2015",
   "Acquisition":"Y",
   "Acquirer":"AbbVie",
   "Acquisition Price ":"350",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":"AbbVie buys last available priority voucher for $350 million"
  },
  {
   "Sponsor":"Y-mAbs Therapeutics",
   "Sponsor-2":"",
   "Year":"2020",
   "Month":"December",
   "Date":"7",
   "name":"Oncology",
   "id":"neuroblastoma",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"DANYELZA",
   "Active Ingredient":"",
   "Treatment Type":"Immunotherapy",
   "MOA":"Monoclonal antibody (anti-GD2)",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"United Therapeutics",
   "Sale  Price (USD, Millions)":"105",
   "Purchase Month":"December",
   "Purchase Date":"28",
   "Purchase Year":"2020",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Ultragenyx",
   "Sponsor-2":"",
   "Year":"2017",
   "Month":"November",
   "Date":"15",
   "name":"Metabolic",
   "id":"Mucopolysaccharidosis Type VII (Sly Syndrome)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"Mepsevii",
   "Active Ingredient":"vestronidase alfa-vjbk",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Novartis",
   "Sale  Price (USD, Millions)":"130",
   "Purchase Month":"December",
   "Purchase Date":"18",
   "Purchase Year":"2017",
   "Acquisition":"N",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Biomarin",
   "Sponsor-2":"",
   "Year":"2014",
   "Month":"March",
   "Date":"12",
   "name":"Metabolic",
   "id":"Morquio A syndrome",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"VIMIZIM",
   "Active Ingredient":"Elosulfase alfa",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"recombinant chimeric monoclonal antibody to GD2",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Regeneron",
   "Sale  Price (USD, Millions)":"68",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"Regeneron",
   "Acquisition Price ":"68",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Origin Biosciences",
   "Sponsor-2":"BridgeBio",
   "Year":"2021",
   "Month":"March",
   "Date":"12",
   "name":"Metabolic",
   "id":"Molybdenum Cofactor Deficiency Type A",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"NULIBRY",
   "Active Ingredient":"fosdenopterin",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"110",
   "Purchase Month":"May",
   "Purchase Date":"13",
   "Purchase Year":"2022",
   "Acquisition":"N",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Orchard Therapeutics",
   "Sponsor-2":"",
   "Year":"2024",
   "Month":"March",
   "Date":"20",
   "name":"Neurology",
   "id":"Metachromatic leukodystrophy(MLD)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"LENMELDY",
   "Active Ingredient":"atidarsagene autotemcel",
   "Treatment Type":"Gene therapy",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":" NA ",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Alexion",
   "Sponsor-2":"",
   "Year":"2019",
   "Month":"July",
   "Date":"1",
   "name":"Metabolic",
   "id":"Lysosomal Acid Lipase deficiency",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"KANUMA",
   "Active Ingredient":"Sebelipase alfa",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"",
   "Redeemed":"Y",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"GW Research",
   "Sponsor-2":"",
   "Year":"2018",
   "Month":"July",
   "Date":"19",
   "name":"Neurology",
   "id":"Lennox-Gastaut Syndrome",
   "Approved Drug":"Y",
   "FDA-Approved Therapy Prior to 2012":"Felbatol; Onfi; Lamictal; Topamax; Banzel",
   "Drug Name":"EPIDIOLEX",
   "Active Ingredient":"cannabidiol",
   "Treatment Type":"Organic Chemicals",
   "MOA":"cannabidiol",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Biohaven",
   "Sale  Price (USD, Millions)":"105",
   "Purchase Month":"March",
   "Purchase Date":"19",
   "Purchase Year":"2019",
   "Acquisition":"N",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Prometic Biotherapeutics",
   "Sponsor-2":"Liminal BioSciences",
   "Year":"2021",
   "Month":"July",
   "Date":"2",
   "name":"Hematology",
   "id":"Hypoplasminogenemia",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"RYPLAZIM",
   "Active Ingredient":"plasminogen, human-tvmh",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"105",
   "Purchase Month":"August",
   "Purchase Date":"9",
   "Purchase Year":"2021",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Alexion",
   "Sponsor-2":"",
   "Year":"2015",
   "Month":"April",
   "Date":"7",
   "name":"Metabolic",
   "id":"Hypophosphatasia (HPP)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"STRENSIQ",
   "Active Ingredient":"asfotase alfa",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"recombinant glycoprotein that contains the catalytic domain (the active site) of TNSALP",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"N",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Eiger BioPharmaceuticals",
   "Sponsor-2":"",
   "Year":"2020",
   "Month":"December",
   "Date":"17",
   "name":"Metabolic",
   "id":"Hutchinson-Gilford Progeria Syndrome (HGPS)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"ZOKINVY",
   "Active Ingredient":"lonafarnib",
   "Treatment Type":"Enzyme inhibitor",
   "MOA":"Protein farnesyltransferase inhibitor",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"AbbVie",
   "Sale  Price (USD, Millions)":"95",
   "Purchase Month":"November",
   "Purchase Date":"23",
   "Purchase Year":"2020",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":"Progeria Research Foundation receives 50% under Collaboration Agreement"
  },
  {
   "Sponsor":"Wellstat Therapeutics",
   "Sponsor-2":"",
   "Year":"2015",
   "Month":"April",
   "Date":"7",
   "name":"Metabolic",
   "id":"Hereditary orotic aciduria",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"Xuriden",
   "Active Ingredient":"uridine triacetate",
   "Treatment Type":"Analogs & derivatives",
   "MOA":"Pyrimidine analogs",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"AstraZeneca",
   "Sale  Price (USD, Millions)":"Undisclosed",
   "Purchase Month":"September",
   "Purchase Date":"9",
   "Purchase Year":"2015",
   "Acquisition":"N",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Novimmune SA - Sobi",
   "Sponsor-2":"",
   "Year":"2018",
   "Month":"December",
   "Date":"13",
   "name":"Hematology",
   "id":"Hemophagocytic lymphohistiocytosis",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"Gamifant",
   "Active Ingredient":"Emapalumab",
   "Treatment Type":"Immunosuppresant",
   "MOA":"Interferon gamma blocking antibody",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"AstraZeneca",
   "Sale  Price (USD, Millions)":"95",
   "Purchase Month":"August",
   "Purchase Date":"22",
   "Purchase Year":"2019",
   "Acquisition":"",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Reata Pharmaceuticals",
   "Sponsor-2":"",
   "Year":"2023",
   "Month":"March",
   "Date":"16",
   "name":"Neurology",
   "id":"Friedreich's ataxia",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"SKYCLARYS",
   "Active Ingredient":"omaveloxolone",
   "Treatment Type":"Peptides",
   "MOA":"Nuclear factor erythroid 2-related factor 2 (Nrf2) activator",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"NA",
   "Purchase Month":"NA",
   "Purchase Date":"NA",
   "Purchase Year":"NA",
   "Acquisition":"Acquisition",
   "Acquirer":"Biogen",
   "Acquisition Price ":"7,300",
   "Acq month":"September",
   "Acq date":"26",
   "Acq year":"2023",
   "":""
  },
  {
   "Sponsor":"Ipsen Biopharmaceuticals",
   "Sponsor-2":"",
   "Year":"2023",
   "Month":"September",
   "Date":"7",
   "name":"Orthopedics",
   "id":"Fibrodysplasia Ossificans Progressiva",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"SOHONOS",
   "Active Ingredient":"palovarotene",
   "Treatment Type":"Hypoglycemic Agents",
   "MOA":"Retinoic acid receptor gamma agonist",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"158",
   "Purchase Month":"August",
   "Purchase Date":"27",
   "Purchase Year":"2024",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Amryt Pharmaceuticals",
   "Sponsor-2":"",
   "Year":"2024",
   "Month":"January",
   "Date":"11",
   "name":"Dermatology",
   "id":"dystrophic epidermolysis bullosa",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"FILSUVEZ",
   "Active Ingredient":"birch triterpenes",
   "Treatment Type":"Gene therapy",
   "MOA":"COL7A1 gene via viral vector",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"Chiesi",
   "Acquisition Price ":"1,705",
   "Acq month":"January",
   "Acq date":"9",
   "Acq year":"2023",
   "":"Under the deal, Chiesi will pay $1.25 billion upfront for Amryt plus up to $225 million more if Amryt's rare skin disease drug Filsuvez can gain an FDA approval and wins a priority review voucher as a result of that nod."
  },
  {
   "Sponsor":"Krystal Biotech",
   "Sponsor-2":"",
   "Year":"2023",
   "Month":"June",
   "Date":"6",
   "name":"Dermatology",
   "id":"dystrophic epidermolysis bullosa",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"VYJUVEK",
   "Active Ingredient":"beremagene geperpavec-svdt",
   "Treatment Type":"Gene therapy",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"100",
   "Purchase Month":"August",
   "Purchase Date":"21",
   "Purchase Year":"2023",
   "Acquisition":"N",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Italfarmaco S.p.A.",
   "Sponsor-2":"",
   "Year":"2024",
   "Month":"March",
   "Date":"21",
   "name":"Neurology",
   "id":"Duchenne muscular dystrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"DUVYZAT",
   "Active Ingredient":"givinostat",
   "Treatment Type":"Enzyme inhibitor",
   "MOA":"Histone deacetylase inhibitor",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Marathon",
   "Sponsor-2":"",
   "Year":"2017",
   "Month":"February",
   "Date":"10",
   "name":"Neurology",
   "id":"Duchenne muscular dystrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"EMFLAZA",
   "Active Ingredient":"deflazacort",
   "Treatment Type":"Immunosuppresant",
   "MOA":"Anti-infllamatory corticosteroid",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"PTC",
   "Acquisition Price ":"190",
   "Acq month":"March",
   "Acq date":"16",
   "Acq year":"2017",
   "":"Sold off Emflaza"
  },
  {
   "Sponsor":"NS Pharma",
   "Sponsor-2":"",
   "Year":"2020",
   "Month":"September",
   "Date":"4",
   "name":"Neurology",
   "id":"Duchenne muscular dystrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"VILTEPSO",
   "Active Ingredient":"viltolarsen",
   "Treatment Type":"Gene therapy",
   "MOA":"Antisense oligonucleotides",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Sarepta Therapeutics",
   "Sponsor-2":"",
   "Year":"2016",
   "Month":"October",
   "Date":"17",
   "name":"Neurology",
   "id":"Duchenne muscular dystrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"EXONDYS 51",
   "Active Ingredient":"eteplirsen",
   "Treatment Type":"Gene therapy",
   "MOA":"Antisense oligonucleotides",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Gilead",
   "Sale  Price (USD, Millions)":"125",
   "Purchase Month":"February",
   "Purchase Date":"21",
   "Purchase Year":"2017",
   "Acquisition":"Y",
   "Acquirer":"Gilead",
   "Acquisition Price ":"125",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Sarepta Therapeutics",
   "Sponsor-2":"",
   "Year":"2020",
   "Month":"January",
   "Date":"23",
   "name":"Neurology",
   "id":"Duchenne muscular dystrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"VYONDYS 53",
   "Active Ingredient":"golodirsen",
   "Treatment Type":"Gene therapy",
   "MOA":"Exon-skipping",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Sarepta Therapeutics",
   "Sponsor-2":"",
   "Year":"2021",
   "Month":"March",
   "Date":"12",
   "name":"Neurology",
   "id":"Duchenne muscular dystrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"AMONDYS 45",
   "Active Ingredient":"casimersen",
   "Treatment Type":"Gene therapy",
   "MOA":"Antisense oligonucleotides",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"N",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Sarepta Therapeutics",
   "Sponsor-2":"",
   "Year":"2023",
   "Month":"July",
   "Date":"17",
   "name":"Neurology",
   "id":"Duchenne muscular dystrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"ELEVIDYS",
   "Active Ingredient":"delandistrogene moxeparvovec-rokl",
   "Treatment Type":"Gene therapy",
   "MOA":"AAV",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"102",
   "Purchase Month":"July",
   "Purchase Date":"5",
   "Purchase Year":"2023",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Vertex",
   "Sponsor-2":"",
   "Year":"2019",
   "Month":"March",
   "Date":"29",
   "name":"Pulmonology",
   "id":"Cystic fibrosis",
   "Approved Drug":"Y",
   "FDA-Approved Therapy Prior to 2012":"TOBI; Cayston; Pulomzyme",
   "Drug Name":"SYMDEKO",
   "Active Ingredient":"tezacaftor/ivacaftor",
   "Treatment Type":"CFTR corrector / CFTR potentiator",
   "MOA":"CFTR corrector / CFTR potentiator",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":" NA ",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Vertex",
   "Sponsor-2":"",
   "Year":"2020",
   "Month":"September",
   "Date":"15",
   "name":"Pulmonology",
   "id":"Cystic fibrosis",
   "Approved Drug":"Y",
   "FDA-Approved Therapy Prior to 2012":"TOBI; Cayston; Pulomzyme",
   "Drug Name":"TRIKAFTA",
   "Active Ingredient":"elexacaftor/tezacaftor/ivacaftor",
   "Treatment Type":"Enzyme inhibitor",
   "MOA":"CFTR modulators",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":" NA ",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Marinus Pharmaceuticals",
   "Sponsor-2":"",
   "Year":"2022",
   "Month":"September",
   "Date":"7",
   "name":"Neurology",
   "id":"cyclin-dependent kinase-like 5 (CDKL5)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"ZTALMY",
   "Active Ingredient":"ganaxolone",
   "Treatment Type":"Enzyme inhibitor",
   "MOA":"GABA receptor modulator",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Novo Nordisk",
   "Sale  Price (USD, Millions)":"110",
   "Purchase Month":"July",
   "Purchase Date":"14",
   "Purchase Year":"2022",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Takeda Pharmaceuticals",
   "Sponsor-2":"",
   "Year":"2024",
   "Month":"January",
   "Date":"11",
   "name":"Hematology",
   "id":"Congenital thrombotic thrombocytopenic purpura (cTTP)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"ADZYNMA",
   "Active Ingredient":"ADAMTS13",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Enzyvant Therapeutics",
   "Sponsor-2":"",
   "Year":"2021",
   "Month":"October",
   "Date":"27",
   "name":"Immunology",
   "id":"Congenital athymia",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"RETHYMIC",
   "Active Ingredient":"allogeneic processed thymus tissue-agdc",
   "Treatment Type":"Biologic",
   "MOA":"Allogeneic thymus tissue therapy",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":" NA ",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"bluebird Bio",
   "Sponsor-2":"",
   "Year":"2022",
   "Month":"October",
   "Date":"7",
   "name":"Neurology",
   "id":"Cerebral adrenoleukodystrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"SKYSONA",
   "Active Ingredient":"elivaldogene autotemcel",
   "Treatment Type":"Gene therapy",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"argenX",
   "Sale  Price (USD, Millions)":"102",
   "Purchase Month":"November",
   "Purchase Date":"30",
   "Purchase Year":"2022",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Regeneron",
   "Sponsor-2":"",
   "Year":"2023",
   "Month":"September",
   "Date":"7",
   "name":"Immunology",
   "id":"CD55-deficient protein-losing enteropathy (PLE) (CHAPLE disease)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"VEOPOZ",
   "Active Ingredient":"pozelimab-bbfg",
   "Treatment Type":"Immunosuppresant",
   "MOA":"TNF-alpha inhibitor",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":" NA ",
   "Purchase Month":"NA",
   "Purchase Date":"Na",
   "Purchase Year":"NA",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Travere Therapeutics",
   "Sponsor-2":"",
   "Year":"2015",
   "Month":"March",
   "Date":"17",
   "name":"Gastroenterology",
   "id":"Bile acid synthesis disorders",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"CHOLBAM",
   "Active Ingredient":"Cholic acid",
   "Treatment Type":"Biologic",
   "MOA":"Cholic acid",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Sanofi",
   "Sale  Price (USD, Millions)":"245",
   "Purchase Month":"May",
   "Purchase Date":"27",
   "Purchase Year":"2015",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Spark Therapeutics",
   "Sponsor-2":"",
   "Year":"2018",
   "Month":"January",
   "Date":"2",
   "name":"Ophthalmology",
   "id":"biallelic RPE65 mutation-associated retinal dystrophy",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"LUXTURNA",
   "Active Ingredient":"voretigene neparvovec",
   "Treatment Type":"Gene therapy",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Jazz",
   "Sale  Price (USD, Millions)":"110",
   "Purchase Month":"Apr",
   "Purchase Date":"30",
   "Purchase Year":"2018",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Biomarin",
   "Sponsor-2":"",
   "Year":"2017",
   "Month":"April",
   "Date":"27",
   "name":"Neurology",
   "id":"Batten disease",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"Brineura",
   "Active Ingredient":"cerliponase alfa",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"hydrolytic lysosomal N-terminal tripeptidyl peptidase",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Novartis",
   "Sale  Price (USD, Millions)":"125",
   "Purchase Month":"November",
   "Purchase Date":"21",
   "Purchase Year":"2017",
   "Acquisition":"Y",
   "Acquirer":"NA",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Mirum Pharmaceuticals",
   "Sponsor-2":"",
   "Year":"2024",
   "Month":"August",
   "Date":"28",
   "name":"Gastroenterology",
   "id":"Alagille syndrome (ALGS)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"LIVMARLI",
   "Active Ingredient":"maralixibat",
   "Treatment Type":"Biologic",
   "MOA":"Ileal bile acid transporter (IBAT) inhibitor",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"110",
   "Purchase Month":"November",
   "Purchase Date":"17",
   "Purchase Year":"2021",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Leadiant Bioscience",
   "Sponsor-2":"",
   "Year":"2018",
   "Month":"October",
   "Date":"25",
   "name":"Immunology",
   "id":"Adenosine deaminase deficiency-SCID",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"REVCOVI",
   "Active Ingredient":"elapegademase-lvlr",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Novartis",
   "Sponsor-2":"",
   "Year":"2017",
   "Month":"September",
   "Date":"11",
   "name":"Oncology",
   "id":"Acute lymphoblastic leukemia",
   "Approved Drug":"Y",
   "FDA-Approved Therapy Prior to 2012":"Arranon; Clolar",
   "Drug Name":"Kymriah",
   "Active Ingredient":"tisagenlecleucel",
   "Treatment Type":"immunotherapy",
   "MOA":"CAR T",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"N",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Pharming",
   "Sponsor-2":"",
   "Year":"2023",
   "Month":"March",
   "Date":"24",
   "name":"Immunology",
   "id":"Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"JOENJA",
   "Active Ingredient":"leniolisib",
   "Treatment Type":"Enzyme inhibitor",
   "MOA":"PI3K-delta inhibitor",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Novartis",
   "Sale  Price (USD, Millions)":"21",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"Novartis",
   "Acquisition Price ":"21",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Sanofi",
   "Sponsor-2":"",
   "Year":"2023",
   "Month":"December",
   "Date":"5",
   "name":"Metabolic",
   "id":"Acid sphingomyelinase deficiency (ASMD)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"Xenpozyme",
   "Active Ingredient":"olipudase alfa-rpcp",
   "Treatment Type":"Enzyme Replacement",
   "MOA":"Acid sphingomyelinase enzyme replacement",
   "Redeemed":"",
   "Purchased":"N",
   "Purchaser":"NA",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"BioMarin",
   "Sponsor-2":"",
   "Year":"2021",
   "Month":"September",
   "Date":"6",
   "name":"Orthopedics",
   "id":"Achondroplasia",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"Voxzogo",
   "Active Ingredient":"",
   "Treatment Type":"Analogs & derivatives",
   "MOA":"CNP analogs",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"110",
   "Purchase Month":"February",
   "Purchase Date":"9",
   "Purchase Year":"2022",
   "Acquisition":"Y",
   "Acquirer":"",
   "Acquisition Price ":"100",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Day One",
   "Sponsor-2":"",
   "Year":"2024",
   "Month":"April",
   "Date":"23",
   "name":"Oncology",
   "id":"Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)",
   "Approved Drug":"N",
   "FDA-Approved Therapy Prior to 2012":"None",
   "Drug Name":"OJEMDA",
   "Active Ingredient":"Tovorafenib",
   "Treatment Type":"Enzyme inhibitor",
   "MOA":"kinase inhibitors",
   "Redeemed":"",
   "Purchased":"Y",
   "Purchaser":"Undisclosed",
   "Sale  Price (USD, Millions)":"108",
   "Purchase Month":"May",
   "Purchase Date":"30",
   "Purchase Year":"2024",
   "Acquisition":"",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  },
  {
   "Sponsor":"Pfizer",
   "Sponsor-2":"",
   "Year":"",
   "Month":"",
   "Date":"",
   "name":"",
   "id":"",
   "Approved Drug":"",
   "FDA-Approved Therapy Prior to 2012":"",
   "Drug Name":"",
   "Active Ingredient":"",
   "Treatment Type":"",
   "MOA":"",
   "Redeemed":"",
   "Purchased":"",
   "Purchaser":"",
   "Sale  Price (USD, Millions)":"",
   "Purchase Month":"",
   "Purchase Date":"",
   "Purchase Year":"",
   "Acquisition":"",
   "Acquirer":"",
   "Acquisition Price ":"",
   "Acq month":"",
   "Acq date":"",
   "Acq year":"",
   "":""
  }
]